EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) on Friday, plunged -12.58% from the previous trading day, before settling in for the closing price of $10.49. Within the past 52 weeks, EYPT’s price has moved between $5.86 and $30.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 69.47%. The company achieved an average annual earnings per share of -22.02%. With a float of $48.73 million, this company’s outstanding shares have now reached $49.04 million.
Let’s determine the extent of company efficiency that accounts for 121 employees. In terms of profitability, gross margin is 91.48%, operating margin of -255.88%, and the pretax margin is -226.38%.
EyePoint Pharmaceuticals Inc (EYPT) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of EyePoint Pharmaceuticals Inc is 8.94%, while institutional ownership is 104.20%. The most recent insider transaction that took place on Oct 23 ’24, was worth 673,355. Before that another transaction happened on Oct 14 ’24, when Company’s Former Director proposed sale 36,975 for $8.92, making the entire transaction worth $329,817.
EyePoint Pharmaceuticals Inc (EYPT) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.33 earnings per share (EPS) for the period topping the consensus outlook (set at -0.48) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.02% per share during the next fiscal year.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
EyePoint Pharmaceuticals Inc (EYPT) is currently performing well based on its current performance indicators. A quick ratio of 5.45 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -2.58 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Looking closely at EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), its last 5-days average volume was 0.75 million, which is a drop from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 9.48%. Additionally, its Average True Range was 0.94.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 26.88%, which indicates a significant increase from 3.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.33% in the past 14 days, which was lower than the 86.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.74, while its 200-day Moving Average is $13.95. However, in the short run, EyePoint Pharmaceuticals Inc’s stock first resistance to watch stands at $10.14. Second resistance stands at $11.10. The third major resistance level sits at $11.65. If the price goes on to break the first support level at $8.63, it is likely to go to the next support level at $8.08. Should the price break the second support level, the third support level stands at $7.12.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
Market capitalization of the company is 547.11 million based on 68,251K outstanding shares. Right now, sales total 46,020 K and income totals -70,800 K. The company made 10,520 K in profit during its latest quarter, and -29,360 K in sales during its previous quarter.
